Recent news on Tarceva

Mystery donor’s gift of £2500 to buy cancer drug  -  25 May 2007
Times & Star,He and his wife, Jean, of Westfield Drive, were trying to raise £2500 to pay for a seven-week trial of Tarceva, which is free on prescription in Scotland

OSI Pharmaceuticals to Present at the Bank of America Health Care ...  -  25 May 2007
Business Wire (press release),OSI's flagship product, Tarceva® (erlotinib), is the first drug discovered and developed by OSI to obtain FDA approval and the only EGFR inhibitor to have

Guidelines on skin reactions to Epidermal Growth Factor Receptor ...  -  25 May 2007
News-Medical.net,The drugs , including erlotinib (Tarceva), cetuximab (Erbitux), and panitumumab (Vectibix) , work by interfering with cell-signaling abnormalities that

Analyst initiations 5-24-07: BKC, NGAS, NWACQ and OSIP  -  25 May 2007
Blogging StocksThinkEquity sees additional upside for Tarceva and started OSI Pharmaceuticals (NASDAQ: OSIP) with a Buy rating and $50 target.

Addition of Tarceva® to Gemzar® Improves Survival in Pancreatic Cancer  -  May 2, 2007
Cancer Consultants (press release),According to an early online publication in the Journal of Clinical Oncology, the addition of the targeted agent Tarceva® (erlotinib) to Gemzar®

Tarceva extends life of patients with pancreatic cancer  -  Apr 29, 2007
News-Medical.net,New results published by the Journal of Clinical Oncology show that adding Tarceva (erlotinib) to gemcitabine chemotherapy significantly improves survival

Tarceva(R) Extends Life of Patients with Pancreatic Cancer  -  Apr 27, 2007
CNW Telbec (Communiqués de presse),Newly published results show significant improvement in survival when innovative, oral cancer drug Tarceva is added to chemotherapy BASEL, Switzerland,

Tarceva(R) Extends Life of Patients with Pancreatic Cancer  -  Apr 25, 2007
Juraforum.de,New results published by the Journal of Clinical Oncology showthat adding Tarceva (erlotinib) to gemcitabine chemotherapysignificantly improves survival by

Tarceva(R) Extends Life of Patients with Pancreatic Cancer  -  Apr 25, 2007
Earthtimes.orgNew results published by the Journal of Clinical Oncology show thatadding Tarceva (erlotinib) to gemcitabine chemotherapy significantlyimproves survival by

Tarceva extends life of patients with pancreatic cancer  -  Apr 26, 2007
Pharma Times (subscription),Switzerland's Roche and its US partner OSI Pharmaceuticals say that new results published in the Journal of Clinical Oncology reveal that adding Tarceva to

Finding may overcome drug resistance in lung cancer  -  May 2, 2007
Cancerfacts.com,Tarceva (erlotinib) is new generation oral anti-cancer drug that targets the human epidermal growth factor receptor. Also known as EGFR, this receptor plays

Targeted drug extends life in pancreatic cancer patients  -  Apr 28, 2007
Cancerfacts.com,BASEL, Switzerland – April 27, 2007 – Adding the drug erlotinib (Tarceva®) to gemcitabine chemotherapy significantly improves survival by 22 percent in

OSI Pharmaceuticals Announces First Quarter 2007 Financial Results  -  Apr 27, 2007
PharmaLive.com (press release),The increase is primarily due to the growth in revenues arising from worldwide Tarceva(R) (erlotinib) sales. Total worldwide net sales of Tarceva for the

OSI Pharmaceuticals to Present at the Citigroup Global Healthcare ...  -  May 14, 2007
PharmaLive.com (press release),OSI's flagship product, Tarceva(R) (erlotinib), is the first drug discovered and developed by OSI to obtain FDA approval and the only EGFR inhibitor to have

Experts warn of global gap in cancer treatment  -  May 10, 2007
Scientific AmericanThe use of Avastin for colorectal cancer in the United States, for example, was 10-times the European average, as was the use of Tarceva for lung cancer.

Ireland Cancer Center Researchers Advance Lung Cancer Treatment  -  Apr 28, 2007
Medical News Today (press release),Tarceva is among a new generation of cancer therapies that disrupt the molecular target responsible for stimulating tumor growth.

OSI Pharmaceuticals to Present at the Citigroup Global Healthcare ...  -  May 14, 2007
Business Wire (press release),OSI's flagship product, Tarceva® (erlotinib), is the first drug discovered and developed by OSI to obtain FDA approval and the only EGFR inhibitor to have

‘Stark inequalities’ in access to cancer drugs  -  May 9, 2007
MSNBCThe biggest differences were seen in four new colorectal and lung cancer drugs — Avastin, or bevacizumab; Erbitux, or cetuximab; Tarceva, or erlotinib;

NZ lags in access to life-saving drugs  -  May 9, 2007
TVNZ,The biggest differences were seen in four new colorectal and lung cancer drugs - Avastin, or bevacizumab; Erbitux, or cetuximab; Tarceva, or erlotinib;

Report blames bureaucracy for UK cancer deaths  -  May 10, 2007
Guardian Unlimited,The lung cancer drug Tarceva (erlotinib) and the bowel cancer drug Avastin (bevacizumab) are used 10 times more in the US than in Europe.

More hopes for pancreatic cancer patients treated with combination ...  -  May 4, 2007
TopCancerNews.com,An early online publication of the Journal of Clinical Oncology states that the addition to the targeted agent Tarceva (erlotinib) to Gemzar (gemcitabine)

AVEO Series D Pulls Down $53M For Cancer Therapies  -  May 3, 2007
BioWorld Online,Another mutation is found at exon 19, and Tarceva (erlotinib, Genentech Inc. and OSI Pharmaceuticals Inc.) has been found to have much more activity in

New mechanism identified for resistance to targeted lung cancer drugs  -  Apr 30, 2007
WebWire (press release),..."We found that, for about 20 percent of patients with tumors that become resistant to Tarceva or Iressa, resistance is caused by the genetic activation of

Fears over NHS cancer drugs cost  -  May 13, 2007
ic Wales,Some drugs, like Herceptin for breast cancer, have won NICE's backing but others like Tarceva, which can extend the life of lung cancer patients,

Cancer care  -  May 14, 2007
InTheNews.co.uk,Some, such as Herceptin for breast cancer, have been approved, while others including Tarceva for lung cancer, have been turned down.

Peptech Acquiring EvoGenix In Cash, Stock Deal Worth A$156M  -  May 7, 2007
BioWorld Online,As an example that neither is necessarily better, he pointed to the EGFR cancer drugs Erbitux (cetuximab, ImClone Systems Inc.) and Tarceva (erlotinib,

Fears over NHS cancer drug costs  -  May 13, 2007
BBC News,Others like Tarceva, which can extend the life of lung cancer patients, have been turned down. Specialists like Nick James, professor of clinical oncology

Tarceva extends life of patients with pancreatic cancer  -  26 Apr 2007
Antara (press release),Basel (ANTARA News/PRNewswire-AsiaNet) - New results published by the Journal of Clinical Oncology show that adding Tarceva (erlotinib) to gemcitabine

A dose of controversy  -  26 Apr 2007
Newsday,When the president of a cancer-fighting foundation implored government advisers to back the drug Tarceva as a treatment for pancreatic cancer,

Scientists Spot Mechanism Behind Lung Cancer Drug Resistance  -  26 Apr 2007
Therapeutics Daily (subscription) (press release),..."While patients respond to drugs like Iressa and Tarceva, the majority of patients become resistant to them. The cancers figure out a way to grow in the

UPI NewsTrack Health and Science News  -  26 Apr 2007
United Press InternationalTarceva is among a new generation of cancer therapies that disrupt the molecular target responsible for stimulating tumor growth.

Insurance offers life-saver cover  -  26 Apr 2007
This is Money,Since then many other NHS cancer patients have been denied vital drugs such as Avastin, which treats bowel cancer, and the lung cancer drug Tarceva,

Biomarkers could drive future of Roche's Tarceva in lung cancer  -  Apr 5, 2007
Pharma Times (subscription),In NSCLC, detection of a specific biomarker could soon identify candidates most likely to respond to targeted therapy with the Swiss firm's Tarceva

Swiss Ask for More Data on Roche's Tarceva  -  Mar 29, 2007
Reuters.uk,VX: Quote, Profile , Research) has submitted more data to Swiss health authorities to try to gain approval for Tarceva for use in pancreatic cancer,

Swiss reject Roche's Tarceva for pancreatic cancer  -  Mar 29, 2007
ReutersRupp said Switzerland's regulatory agency, Swissmedic, had questioned the safety and efficacy of Tarceva and the approval process had not got as far as the

Swiss Reject Roche's Tarceva for Pancreatic Cancer  -  Mar 29, 2007
Reuters.uk,VX: Quote, Profile , Research) Tarceva for use in pancreatic cancer, the company said on Thursday. "We've actually applied for the approval and they said no

Roche's Tarceva not to receive regulatory approval in Switzerland ...  -  Mar 28, 2007
Hemscott,ZURICH (AFX) - Roche Holding AG's cancer drug Tarceva will not receive approval by Switzerland's regulatory authority, the Bundesamt for Gesundheit (BAG)

Stocks: OSI pays off after a long wait  -  Apr 16, 2007
Crain's New York Business,Much of the credit goes to wonder drug Tarceva, proven effective against cancers of the pancreas and lungs. As more doctors around the world write Tarceva

Cancer drug lottery  -  Apr 11, 2007
Times & Star,Harry and Jean White, of Westfield Drive, Workington, are trying to raise £2500 for a seven-week trial of new drug Tarceva. Mr White, 73, was diagnosed with

Cyclacel Pharmaceuticals reports preclinical Seliciclib-Erlotinib ...  -  Apr 18, 2007
PipelineReview.com (press release),...an orally-available cyclin dependent kinase (CDK) inhibitor, with epidermal growth factor receptor (EGFR) inhibitor erlotinib (Tarceva(R)).

OSI Pharmaceuticals to Announce First Quarter and Financial ...  -  Apr 16, 2007
PharmaLive.com (press release),OSI's flagship product, Tarceva(R) (erlotinib), is the first drug discovered and developed by OSI to obtain FDA approval and the only EGFR inhibitor to have

Nicola's memory inspires others  -  Apr 18, 2007
Crewe Guardian,Derek Shields' stepdaughter Nicola Penketh died last year after she was deprived of Tarceva, a drug they believe would have saved her.

End this border drugs lottery  -  Apr 11, 2007
News & Star,Chemotherapy and radiotherapy have failed to beat the disease but now Harry has been offered a trial of a new drug, Tarceva.

Erbitux Misses In Pancreatic Cancer, Dropping ImClone  -  Apr 11, 2007
BioWorld Online,..."The low hurdle set by Tarceva means that any positive data in pancreatic cancer would have been huge," Mack said of Erbitux. "I think people expected that

ImClone Loses an Indication  -  Apr 17, 2007
Motley FoolOSI Pharmaceuticals' (Nasdaq: OSIP) Tarceva is the only targeted therapy indicated for use in pancreatic cancer. What makes the Erbitux results somewhat

Erbitux failed to help pancreatic cancer patients  -  Apr 13, 2007
TopCancerNews.com,If approved, Erbitux will compete with Tarceva, sold by Roche Holding AG, Genentech Inc., and OSI Pharmaceuticals Inc. as a treatment for pancreatic and

Biologic Drug Erbitux Proves Disappointing as Treatment for ...  -  Apr 12, 2007
Biologic Drug Report,The disappointing results leave biologic Tarceva, a drug sold by Roche Holding AG, Genentech Inc. and OSI Pharmaceuticals Inc., as the principal treatment

Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor ...  -  Apr 19, 2007
PR Newswire (press release),Moreover, in combination with Tarceva, MP470 inhibited Akt phosphorylation in LNCaP prostate cells. Finally, the MP470/Tarceva treatment was shown to

Genentech Beats on Bottom Line  -  Apr 11, 2007
TheStreet.comTarceva's $102 million in revenue was 10% better than the first quarter of 2006, but was roughly $10 million below analysts' targets.

Genentech Q1 2007 Earnings Call Transcript  -  Apr 11, 2007
Seeking Alpha,Turning to Tarceva. Our broad program examining Tarceva as treatment for non small-cell lung cancer continues. In 2007 we expect to complete enrollment in

Spectrum Pharmaceuticals Announces Data From Three Oncology ...  -  Apr 19, 2007
PR Newswire (press release),Erlotinib (Tarceva(R)) is a potent inhibitor of the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). Since upregulation of the Erk and

Roche Posts Strong First Quarter Sales – Upgrade of Core Earnings ...  -  Apr 18, 2007
PharmaLive.com (press release),Tarceva sales grew by 44%, reflecting increased usage in second-line, non-small cell lung cancer (NSCLC) in existing markets as well as the launch in new

Cancer Drugs A Key In MedImmune Purchase  -  Apr 23, 2007
Forbes,These pills are becoming a mainstay of cancer treatment since the arrival of drugs like Tarceva, for non-small lung cancer, and Gleevec,

THE RATINGS GAME Genentech downgraded on near-term growth  -  Apr 12, 2007
MarketWatchAnd he now expects sales of nonsmall-cell lung cancer and pancreatic cancer treatment Tarceva to total $420 million for the full-year period vs. a prior

Analysis: Genentech's Q1 disappoints  -  Apr 12, 2007
United Press InternationalKing reduced his sales estimates for Avastin, Rituxan, Herceptin, Lucentis and Tarceva. His Avastin forecast dropped from $2.36 billion to $2.26 billion,

Study: Marijuana halts growth of lung cancer tumors  -  Apr 22, 2007
Indianapolis Star,The group includes Erbitux, which treats colon and head and neck cancers; Vectibix, which treats colon cancer; Genentech's Tarceva, approved for lung and

Infinity and MedImmune to Present Preclinical Data From Study of ...  -  Apr 10, 2007
PharmaLive.com (press release),NSCLC patients with mutations in EGFR have been found to benefit from drugs such as Tarceva(r) and Iressa(r) that block EGFR signaling.

Don't use public funds for stem-cell research  -  Apr 21, 2007
DesMoinesRegister.com,The group includes Erbitux, which treats colon and head and neck cancers; Vectibix, which treats colon cancer; OSI Pharmaceuticals' Tarceva, approved for

Pot shrank mouse lung tumors  -  Apr 18, 2007
Denver Post,The group includes Erbitux, which treats colon and head and neck cancers; Vectibix, which treats colon cancer; Genentech Inc.'s Tarceva, approved for lung

AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral ...  -  Apr 17, 2007
PharmaLive.com (press release),The molecularly targeted drugs - erlotinib (Tarceva(R)) and gefitinib (Iressa(R)) - inhibit EGFR kinase activity and are important therapies for patients

AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral ...  -  Apr 17, 2007
Business Wire (press release),The molecularly targeted drugs – erlotinib (Tarceva ® ) and gefitinib (Iressa ® ) - inhibit EGFR kinase activity and are important therapies for patients

Ascenta Therapeutics Highlights Multiple Data Presentations at ...  -  Apr 13, 2007
Genetic Engineering News (press release),Therapeutics inhibitor erlotinib (Tarceva(R)) ---------------------------------- -------------- A novel pan inhibitor of Bcl-2 and Xiongwen Mcl-1,

Genentech financially strong while Amgen struggles  -  Apr 13, 2007
BiopharmaReporter.com,Moreover, the company reported that sales of its non-small cell lung cancer Tarceva (erlotinib) grew 10 per cent to $102m, while Lucentis (ranibizumab

ImClone slides as pancreatic cancer trial misses mark  -  Apr 12, 2007
BiopharmaReporter.com,...which will assess Avastin and Gemzar with either Erbitux or another recently-launched pancreatic cancer drug, Genentech/Roche's Tarceva (erlotinib).

Genentech earnings soar but Lucentis sales slow down slightly  -  Apr 12, 2007
Pharma Times (subscription),As for Genentech's other key products, US sales of the breast cancer drug Herceptin (trastuzumab) climbed just 7% to $311 million, while Tarceva (erlotinib)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional